Clinical Trials Browser

Phase 3 × Has announcements × Nivolumab × Clear all

NCT03907488 2026-04-13

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Phase 3 Active not recruiting

994 enrolled 11 charts 2 FDA

Hodgkin Disease

NCT04099251 2026-04-09

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 2 FDA

Melanoma

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 2 FDA

Urothelial Cancer

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 2 FDA

Various Advanced Cancer

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02743494 2025-11-18

CheckMate 577

Phase 3 Completed

794 enrolled 13 charts 2 FDA

Advanced Cancer

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02632409 2025-10-16

CheckMate 274

Phase 3 Active not recruiting

709 enrolled 13 charts 2 FDA

Various Advanced Cancer

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT04810078 2025-10-09

CheckMate-67T

Phase 3 Active not recruiting

681 enrolled 3 FDA

Carcinoma, Renal Cell

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 3 FDA

Gastrointestinal

Colorectal Neoplasms

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 2 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 2 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 2 FDA

Carcinoma, Renal Cell

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 2 FDA

Melanoma

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 3 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Completed

419 enrolled 20 charts 3 FDA

Gastrointestinal

Esophageal Neoplasms